SOD1 and amyotrophic lateral sclerosis: Accordingly, unsupervised comparison of the CSF targeted proteome from the patients of the discovery cohort and the additional ones analyzed after 12 months of treatment did not highlight any clustering between the 2 subgroups of SOD1‐ALS patients (Fig. S14B).